Drug class
Purine Analogues
Purine analogues are a class of antimetabolite medications chemically structured to mimic endogenous purine nucleosides and bases, such as adenine and guanine. Read more about Purine Analogues
75 drugs in this class 47 manufacturers
Drugs in Purine Analogues
CLOFARABINE
AZATHIOPRINE SODIUM
CLOFARABINE
MAVENCLAD (cladribine)
MAVENCLAD (cladribine)
MAVENCLAD (cladribine)
MAVENCLAD (cladribine)
MAVENCLAD (cladribine)
Purine analogues are a class of antimetabolite medications chemically structured to mimic endogenous purine nucleosides and bases, such as adenine and guanine.
Once incorporated into target cells and metabolically activated, they disrupt cellular proliferation by competing with natural substrates, inhibiting key enzymes in purine biosynthesis and DNA replication, and causing DNA strand termination or damage.
Therapeutically, these agents are primarily indicated for the treatment of hematologic malignancies, including acute leukemias, chronic lymphocytic leukemia, and hairy cell leukemia, as well as selected autoimmune conditions like multiple sclerosis and inflammatory bowel disease.
-
fda.gov
Purine analogues are a class of antimetabolite medications chemically structured to mimic endogenous purine nucleosides and bases, such as adenine and guanine Once incorporated into target cells and metabolically activated, they disrupt cellular proliferation by competing with natural substrates, inhibiting key enzymes in purine biosynthesis and DNA replication, and causing DNA strand termination or damage
-
fda.gov
Purine analogues are a class of antimetabolite medications chemically structured to mimic endogenous purine nucleosides and bases, such as adenine and guanine Once incorporated into target cells and metabolically activated, they disrupt cellular proliferation by competing with natural substrates, inhibiting key enzymes in purine biosynthesis and DNA replication, and causing DNA strand termination or damage Therapeutically, these agents are primarily indicated for the treatment of hematologic mal...
-
fda.gov
Once incorporated into target cells and metabolically activated, they disrupt cellular proliferation by competing with natural substrates, inhibiting key enzymes in purine biosynthesis and DNA replication, and causing DNA strand termination or damage Therapeutically, these agents are primarily indicated for the treatment of hematologic malignancies, including acute leukemias, chronic lymphocytic leukemia, and hairy cell leukemia, as well as selected autoimmune conditions like multiple sclerosis ...
-
fda.gov
Therapeutically, these agents are primarily indicated for the treatment of hematologic malignancies, including acute leukemias, chronic lymphocytic leukemia, and hairy cell leukemia, as well as selected autoimmune conditions like multiple sclerosis and inflammatory bowel disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.